Completed PHASE2 INTERVENTIONAL NCT00384423

Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept

A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimer's Disease.

Sponsor: Epix Pharmaceuticals, Inc.

Conditions Alzheimer's Disease

Interventions PRX-03140

Updated 6 times since 2017 Last updated: Jan 29, 2008 Started: Oct 31, 2006 Primary completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alzheimer's Disease and is currently completed. Epix Pharmaceuticals, Inc. leads this study, which shows 6 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Epix Pharmaceuticals, Inc.

Data source: Epix Pharmaceuticals, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Darien, United States , Dayton, United States , Greenville, United States , Jenkintown, United States , Miami, United States , Paramount, United States , Pittsfield, United States , Plantation, United States , Rancho Mirage, United States and 6 more locations